Orient Bio

Orient Bio Financing Cash Flow

The Net Financing Cash Flow of Orient Bio (002630.KS) as of Oct 27, 2026 is 3.87 B KRW. In the previous year, Net Financing Cash Flow was -2.58 B KRW — a change of -249.96% (higher).

Financing Cash Flow

3.87 BKRW

YoY

-249.96%

Last updated:

Net Financing Cash Flow of Orient Bio is 2021 3.87 B KRW. Net Financing Cash Flow of Orient Bio was 2020 -2.58 B KRW. It decreases by -249.96% higher compared to the previous year.

The Orient Bio Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2014
9.64 B KRW
Jan 1, 2015
6.56 B KRW
Jan 1, 2016
25.53 B KRW
Jan 1, 2017
20.78 B KRW
Jan 1, 2018
33.92 B KRW
Jan 1, 2019
23.00 B KRW
Jan 1, 2020
-2.58 B KRW
Jan 1, 2021
3.87 B KRW
The Orient Bio Financing Cash Flow history
YEARFinancing Cash FlowYoY
3.87 BKRW-249.96%
-2.58 BKRW-111.23%
23.00 BKRW-32.18%
33.92 BKRW+63.24%
20.78 BKRW-18.60%
25.53 BKRW+289.05%
6.56 BKRW-31.96%
9.64 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Orient Bio Stock analysis

What does Orient Bio do? Orient Bio Inc generates revenue through the production and supply of laboratory animals such as mice, rats, guinea pigs, hamsters, SPF rabbits, and beagles. The company also offers CRO services including safety assessments and new drug development, alongside medical and library equipment like barrier systems. Additional income comes from support services such as rodent surgery, laboratory diagnostics, transgenic services, and genetic testing. The firm further provides feeds, reagents, disinfectants, automobile components, power supply equipment, and other machines through its subsidiaries. Orient Bio Inc's primary customers include research institutions, pharmaceutical companies, and medical facilities requiring laboratory animals and specialized services. The company's product segments consist of live animals, CRO services, medical equipment, and ancillary products like feeds and reagents. Subsidiaries contribute to revenue by supplying complementary items such as disinfectants and power supply equipment. The business model leverages a diversified portfolio of biotechnology products and services, targeting both direct research and development needs and ancillary support requirements. Revenue streams are derived from the sale of animals, provision of CRO services, equipment sales, and subsidiary product lines, ensuring steady income across multiple segments. Orient Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Orient Bio stock

Net Financing Cash Flow of Orient Bio is 3.87 B KRW in 2021.

Net Financing Cash Flow of Orient Bio changed from -2.58 B KRW to 3.87 B KRW, representing a -249.96% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Orient Bio since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Orient Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Orient Bio

All Key Metrics — Orient Bio